Shares of Incyte fell 20% on Friday after a combo therapy with drug giant Merck failed in a study. In a melanoma combo therapy that combined drugs from Incyte and Merck, failed to meet the main goal in a study. Incyte’s epacadostat, an IDO inhibitor that blocks an enzyme that protects tumors from the immune … Continue reading “Incyte Shares Fall after Combo Drug with Merck Failed in Study”
Tag: incyte
Biotech & Pharma
Eli Lilly Shares Fall After FDA Rejection
Eli Lilly didn't wake up to a good day on Monday as shares plummeted after…
April 17, 2017